These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 34550621)

  • 1. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.
    Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Shenhar-Tsarfaty S; Mirelman A
    J Neurol; 2021 Apr; 268(4):1517-1525. PubMed ID: 33388928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers.
    Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Shirvan JC; Cedarbaum JM; Orr-Urtreger A; Regev K; Shenhar-Tsarfaty S; Mirelman A
    J Parkinsons Dis; 2021; 11(3):1285-1296. PubMed ID: 33998549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.
    Thaler A; Shenhar-Tsarfaty S; Shaked Y; Gurevich T; Omer N; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Giladi N; Mirelman A
    Sci Rep; 2020 Jun; 10(1):9329. PubMed ID: 32518334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2020 Jul; 35(7):1249-1253. PubMed ID: 32353202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
    Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
    Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
    Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
    Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of p.G2019S Mutation in the
    Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
    J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.
    Bregman N; Thaler A; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N;
    Brain Struct Funct; 2017 Apr; 222(3):1207-1218. PubMed ID: 27401793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha galactosidase A activity in Parkinson's disease.
    Alcalay RN; Wolf P; Levy OA; Kang UJ; Waters C; Fahn S; Ford B; Kuo SH; Vanegas N; Shah H; Liong C; Narayan S; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Oliva P; Keutzer J; Marder K; Zhang XK
    Neurobiol Dis; 2018 Apr; 112():85-90. PubMed ID: 29369793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
    Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
    J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Ortega RA; Bressman SB; Raymond D; Ozelius LJ; Katsnelson V; Leaver K; Swan MC; Shanker V; Miravite J; Wang C; Bennett SAL; Saunders-Pullman R
    Mov Disord; 2022 Nov; 37(11):2217-2225. PubMed ID: 36054306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
    Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
    JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
    Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
    Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
    Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
    Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2/GBA mutated Parkinson's disease.
    Lin F; Ruan X; Zou X; Weng H; Zeng Y; Zheng J; Ye Q; Meng F; Chen X; Cai G
    CNS Neurosci Ther; 2024 Jun; 30(6):e14728. PubMed ID: 38837664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.